Director of AI Research, AI for Oncology Clinical Development

We're building a connected, end-to-end Enterprise AI engine - uniting data foundations, AI technology, process reinvention, and business-facing AI to accelerate results across the whole value chain. Success depends on being exceptional connectors: you'll actively leverage existing capabilities, celebrate and promote reuse, export breakthrough ideas across geographies and functions, and obsess over scaling impact rather than building in isolation. If you thrive in high-collaboration environments where your role is to turn complex, cross-functional problems into reusable, enterprise-wide capabilities - and where the measure of success is adoption and scale, not just innovation - you'll have the platform (and sponsorship) to make it real.

AI Science & Innovation (AISI) sits at the centre of AstraZeneca's R&D AI transformation. Our remit is to build, buy and deliver the AI models and agents that change pipeline outcomes, across discovery, translational science, biomarkers and clinical development.

Drug discovery has benefitted enormously in the current AI era, yet comprises only a portion of the journey to bring new treatments to those in need. The final step - clinical drug development - is oft overlooked, despite requiring a significant proportion of time and investment. In the AI for Clinical Development team at AstraZeneca, we're reimagining the process of clinical development. Our vision is to bring safe, efficacious treatments to patients in a way that quantifiably improves our chance to do this faster, more cost-effectively, and with reduced patient burden.

In this role, you will be a senior technical and strategic lead to help us leverage the power of AI to the fullest, alongside our other computational, statistical, and machine learning tools. You will work across the enterprise to define and deliver on AstraZeneca's most pressing clinical development questions. You will proactively collaborate in cross-functional teams spanning AstraZeneca's key Oncology foci of hematology, cell therapy, antibody-drug conjugates, small molecules, and biologics. This is an unprecedented, high visibility opportunity to invent new ways to leverage data, models, and learnings across the spectrum of cancer biology and drug modalities - and importantly, you and the team will apply these new methods to measurably advance the late-stage drug pipeline and our group's ambition.